Abstract
Risk of myocarditis in patients with cancer treated with immune checkpoint inhibitors
Highlights
The field of oncology has changed immensely since the advent of immune checkpoint inhibitors (ICIs). Cancers, such as advanced melanoma, previously carried a prognosis of 8-10 months, patients have a chance at remission [1]
This discovery lead to the development of ipilimumab, a monoclonal antibody targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) which is currently approved for treatment of advanced melanoma [8]
Cardiotoxicity is an important complication of ICI therapy, and quite rare, when it does occur it commonly proves fatal for the patient
Summary
Risk of myocarditis in patients with cancer treated with immune checkpoint inhibitors. Matthew Kelling MS1; Michelle Dimza; Samir Dalia MD2* 1Kansas City University of Medicine and Biosciences, Kansas City, Missouri, USA 2Adjunct Clinical Assistant Professor of Hematology/Oncology, Kansas City University of Medicine and Biosciences, Joplin, Missouri, USA. Received: March 30, 2018 Accepted: June 01, 2018 Published Online: June 07, 2018 Journal: Chronicles of Oncology Publisher: MedDocs Publishers LLC Online edition: http://meddocsonline.org/ Copyright: © Dalia S (2018).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
